Abstract
We compared the amount of serum Epstein‐Barr virus DNA (EBV‐DNA) detected in patients with nasopharyngeal carcinoma (NPC) in a high‐incidence area, represented by Taiwan, and a low‐incidence area, represented by Japan, using real‐time quantitative PCR. The median serum EBV‐DNA value in 41 Japanese NPC cases was 5450 copies/ml, and that in in 23 Taiwanese cases was 2125 copies/ml. The median serum EBV‐DNA value in all 64 NPC cases was significantly higher than in control groups. Using receiver‐operating‐characteristic (ROC) curves, the sensitivity and specificity of EBV‐DNA quantification were determined (cut‐off point, 6.87 copies/ml; sensitivity, 0.855; specificity, 0.885) and compared with those of EBV‐viral‐capsid‐antigen (VCA) titers; the results showed that EBV‐DNA was a more sensitive and specific parameter than EBV‐VCA titer. Then, we analyzed 19 NPC patients in whom recurrence developed (11 Japanese and 8 Taiwanese), and 26 NPC patients in continuous remission. Although there was no significant difference in EBV‐DNA values between Japanese and Taiwanese patients, the value was significantly higher in the 19 patients with recurrence than in those in remission. ROC analysis again revealed a higher diagnostic value of EBV‐DNA than EBV‐VCA. These results suggest EBV‐DNA is a more reliable tumor marker than EBV‐VCA in both high‐incidence and low‐incidence areas of NPC.
Abbreviations:
- NPC
nasopharyngeal carcinoma
- EBV
Epstein‐Barr virus
- ROC
receiver‐operating‐characteristics
- VCA
viral capsid antigen
- RQ‐PCR
real‐time quantitative PCR
- NHL
non‐Hodgkin's lymphoma
- HNSCC
head and neck squamous cell carcinoma
References
- 1. Ho JHC. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978; 4: 183–205. [PubMed] [Google Scholar]
- 2. Lu CC, Chen JC, Jin Y‐T, Yang HB, Chan S‐H, Tsai S‐T. Genetic susceptibility to nasopharyngeal carcinoma within the HLA‐A locus in Taiwanese. Int J Cancer, 2003; 103: 745–51. [DOI] [PubMed] [Google Scholar]
- 3. Epstein MA, Achong BG, editors. The Epstein‐Barr virus. New York , Berlin , Heidelberg : Springer‐Verlag; 1979. p. 422–5. [Google Scholar]
- 4. Sawaki S. The epidemiology of nasopharyngeal carcinoma. In: Sawaki S, editor. The basic and clinical study of nasopharyngeal carcinoma. The homework report of the Eightieth Japan Otorhinolaryngological Symposium, Tokyo , Japan , 4–34, 1979. [Google Scholar]
- 5. Takeshita H, Furukawa M, Fujieda S. Epidemiological research into nasopharyngeal carcinoma in the Chubu region of Japan. Auris Nasus Larynx 1999; 26: 277–89. [DOI] [PubMed] [Google Scholar]
- 6. Muir CS. Nasopharyngeal carcinoma in non‐Chinese populations with special reference to south‐east Asia and Africa. Int J Cancer 1971; 8: 351–63. [DOI] [PubMed] [Google Scholar]
- 7. Lo YMD, Chan LY, Lo K, Leung S, Zhang S, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative analysis of cell‐free Epstein Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59: 1188–91. [PubMed] [Google Scholar]
- 8. Lo YMD, Chan LY, Chan AT, Leung S, Lo K, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative and temporal correlation between circulating cell‐free Epstein‐Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999; 59: 5452–5. [PubMed] [Google Scholar]
- 9. Lo YMD, Leung S, Chan LY, Chan AT, Lo K, Johnson PJ, Huang DP. Kinetics of plasma Epstein‐Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000; 60: 2351–5. [PubMed] [Google Scholar]
- 10. Lo YMD, Chan AT, Chan LY, Leung S, Lam C, Huang DP, Johnson PJ. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein‐Barr virus DNA. Cancer Res 2000; 60: 6878–81. [PubMed] [Google Scholar]
- 11. Chan ATC, Lo YMD, Zee B, Chan LYS, Ma BBY, Leung S‐F, Mo F, Lai M, Huang DP, Johnson PJ. Plasma Epstein‐Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614–9. [DOI] [PubMed] [Google Scholar]
- 12. Chan KH, Gu YL, Ng F, Ng PSP, Seto WH, Sham JST, Chua D, Wei W, Chen YL, Luk W, Zong YS, Ng MH. EBV specific antibody‐based and DNA‐based assays in serologic diagnosis of nasopharyngeal carcinoma. Int J Cancer 2003; 105:706–9. [DOI] [PubMed] [Google Scholar]
- 13. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. Philadelphia : JB Lippincott; 1997. p. 31–3. [Google Scholar]
- 14. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, Matsuyama T, Morishima T. Quantitative analysis of Epstein‐Barr virus load by using real‐time PCR assay. J Clin Microbiol 1999; 37: 132–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristics (ROC) curve. Radiology 1982; 143: 29–36. [DOI] [PubMed] [Google Scholar]
- 16. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operatimg characteristic (ROC) curve. Radiology 1983; 148: 839–43. [DOI] [PubMed] [Google Scholar]
- 17. Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Mutirangura A. Epstein‐Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 2000; 6: 1046–51. [PubMed] [Google Scholar]
- 18. Hsiao J, Jin Y, Tsai S. Detection of cell free Epstein‐Barr virus DNA in sera from patients with nasopharyngeal carcinoma. Cancer 2000; 94: 723–9. [DOI] [PubMed] [Google Scholar]
- 19. Naegele RF, Champion J, Murphy S, Henle G, Henle W. Nasopharyngeal carcinoma in American children: Epstein‐Barr virus‐specific antibody titers and prognosis. Int J Cancer 1989; 29: 209–12. [DOI] [PubMed] [Google Scholar]
- 20. Tamada A, Makimoto K, Yamabe H, Imai J, Himura Y, Oyagi A, Araki T. Titers of Epstein‐Barr virus‐related antibodies in nasopharyngeal carcinoma in Japan. Cancer 1984; 53: 430–40. [DOI] [PubMed] [Google Scholar]
- 21. Henle W, Ho JHC, Henle G, Chau JCW, Kwan HC. Nasopharyngeal carcinoma: significance of changes in Epstein‐Barr virus‐related antibody patterns following therapy. Int J Cancer 1977; 20: 663–72. [DOI] [PubMed] [Google Scholar]
- 22. Hadar T, Rahima M, Kahan E, Sidi J, Rakowsky E, Sarov B, Sarov I. Significance of specific Epstein‐Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharygeal carcinoma patients. J Med Virol 1986; 20: 329–39. [DOI] [PubMed] [Google Scholar]